Regional differences in predictive accuracy of WHO immunologic failure criteria

AIDS

Volumn 26, Issue 6, 2012, Pages 768-770

  Kiragga, Agnes N ^a   Castelnuovo, Barbara ^a   Kamya, Moses R ^a   Moore, Richard ^b   Manabe, Yukari C ^a,b  

^a MAKERERE UNIVERSITY   (Uganda)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ACCURACY; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICA; AIDS PATIENT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; DRUG TREATMENT FAILURE; HUMAN; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UGANDA; UNITED STATES; WORLD HEALTH ORGANIZATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HUMANS; MALE; RESIDENCE CHARACTERISTICS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE; UGANDA; UNITED STATES; VIRAL LOAD;

EID: 84859090159     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835143e3     Document Type: Article

References (21)

1. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendation for a public health approach. 2010. http://whqlibdoc.who.int/publications/2010/9789241599764-eng.pdf. [Accessed on 2 January 2012].
2. Kimmel AD, Weinstein MC, Anglaret X, Goldie SJ, Losina E, Yazdanpanah Y, et al. Laboratory monitoring toguide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr 2010; 54:258-268.
3. Reynolds SJ, Nakigozi G, Newell K, Ndyanabo A, Galiwongo R, Boaz I, et al. Failure ofimmunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS 2009; 23:697-700.
4. Moore DM, Awor A, Downing R, Kaplan J, Montaner JS, Hancock J, et al. CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 49:477-484.
5. van Oosterhout JJ, Brown L, Weigel R, Kumwenda JJ, Mzinganjira D, Saukila N, et al. Diagnosis ofantiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria. Trop Med Int Health 2009; 14:856-861.
6. Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD. Evaluation ofthe WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008; 22:1971-1977.
7. Castelnuovo B, Kiragga A, Schaefer P, Kambugu A, Manabe Y. High rate ofmisclassification of treatment failure based on WHO immunological criteria. AIDS 2009; 23:1295-1296; author reply 1296.
8. Hermans SM, Kiragga AN, Schaefer P, Kambugu A, Hoepelman AI, Manabe YC. Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa. PLoS One 2010; 5:e10527.
9. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005; 19:2109-2116. (Pubitemid 41668999)
10. Castelnuovo B, Manabe YC, Kiragga A, Kamya M, Easterbrook P, Kambugu A. Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis 2009; 49:965-972.
11. Moore RD. Understanding the clinical and economic outcomes of HIV therapy: the Johns Hopkins HIV clinical practice cohort. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17 (Suppl 1):S38-S41. (Pubitemid 128708058)
12. Vasan A, Renjifo B, Hertzmark E, Chaplin B, Msamanga G, Essex M, et al. Different rates ofdisease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis 2006; 42:843-852. (Pubitemid 43363943)
13. Kiwanuka N, Robb M, Laeyendecker O, Kigozi G, Wabwire- Mangen F, Makumbi FE, et al. HIV-1 viral subtype differences in the rate of CD4+ T-cell decline among HIV seroincident antiretroviral naive persons in Rakai district, Uganda. J Acquir Immune Defic Syndr 2010; 54:180-184.
14. Bousheri S, Burke C, Ssewanyana I, Harrigan R, Martin J, Hunt P, et al. Infection with different HIV subtypes is associated with CD4 activation-associated dysfunction and apoptosis. J Acquir Immune Defic Syndr 2009; 52:548-552.
15. Kosakovsky Pond SL, Smith DM. Are all subtypes created equal? The effectiveness of antiretroviral therapy against nonsubtype B HIV-1. Clin Infect Dis 2009; 48:1306-1309.
16. Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, Parkin N, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23:1127-1134.
17. Sigaloff KC, Hamers RL, Wallis CL, Kityo C, Siwale M, Ive P, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr 2011; 58:23-31.
18. Keiser O, Chi BH, Gsponer T, Boulle A, Orrell C, Phiri S, et al. Outcomes ofantiretroviral treatment in programmes with and without routine viral load monitoring in southern Africa. AIDS 2011; 25:1761-1769.
19. Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, Conradie F, et al. HIV-1 drug resistance inantiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011; 11:750-759.
20. Nakanjako D, Kyabayinze DJ, Mayanja-Kizza H, Katabira E, Kamya MR. Eligibility for HIV/AIDS treatment among adults in a medical emergency setting at an urban hospital in Uganda. Afr Health Sci 2007; 7:124-128.
21. Sabin CA, Smith CJ, d'Arminio Monforte A, Battegay M, Gabiano C, Galli L, et al. Response tocombination antiretroviral therapy: variation by age. AIDS 2008; 22:1463-1473.